6 drug(s) with this reaction
4,773 total reports
White Blood Cell Count Decreased has been reported as an adverse reaction across 6 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 4,773 adverse event reports mention white blood cell count decreased in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with white blood cell count decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have white blood cell count decreased listed in their FDA adverse event reports, sorted by report count:
In addition to white blood cell count decreased, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
6 drug(s) manufactured by Amgen Inc have white blood cell count decreased listed in their FDA adverse event reports: DENOSUMAB, FILGRASTIM, PEGFILGRASTIM, DARBEPOETIN ALFA, PANITUMUMAB, and others.
There are a combined 4,773 reports of white blood cell count decreased across 6 Amgen Inc drug(s) in the FDA adverse event database.